Abiopharma

🔍 FRISSORA MARK P (Executive)

Company: BIOADAPTIVES, INC. (BDPT)

Report Date: 2026-01-01-05:00

Detailed Transactions and Holdings:

• Acquired 228,600 shares of Series D Convertible Preferred Stock (Derivative)
  Date: 2026-01-01-05:00 | Code: J | Exercise: 2026-07-01-05:00 | equity_swap_involved: false | shares_owned_after: 57,217.00 | transaction_form_type: 4 | Footnotes: F2, F1, F1, F2

Footnotes:

• F1: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and theReporting Person.
• F2: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares ofcommon stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six monthsafter the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting ofstockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire.